AUB ScholarWorks

Browsing by Author "d.pennell@ic.ac.uk"

Browsing by Author "d.pennell@ic.ac.uk"

Sort by: Order: Results:

  • Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload 
    Pennell D.J.; Porter J.B.; Cappellini M.D.; Chan L.L.; El-Beshlawy A.; Aydinok Y.; Ibrahim H.; Li C.-K.; Viprakasit V.; Elalfy M.S.; Kattamis A.; Smith G.; Habr D.; Domokos G.; Roubert B.; Taher A. (PAVIAVIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY, 2011)
    Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of ...
  • Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major 
    Pennell D.J.; Porter J.B.; Cappellini M.D.; Chan L.L.; El-Beshlawy A.; Aydinok Y.; Ibrahim H.; Li C.-K.; Viprakasit V.; Elalfy M.S.; Kattamis A.; Smith G.; Habr D.; Domokos G.; Roubert B.; Taher A. (PAVIAVIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY, 2012)
    Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue ...
  • Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia 
    Pennell D.J.; Porter J.B.; Cappellini M.D.; El-Beshlawy A.; Chan L.L.; Aydinok Y.; Elalfy M.S.; Sutcharitchan P.; Li C.-K.; Ibrahim H.; Viprakasit V.; Kattamis A.; Smith G.; Habr D.; Domokos G.; Roubert B.; Taher A. (WASHINGTON2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, 2010)
    Cardiac iron overload causes most deaths in β-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac iron overload was assessed in 192 patients with β-thalassemia in a 1-year prospective, multicenter ...

Search AUB ScholarWorks

Browse

My Account